ACOR vs. SCNI, ACORQ, TCBP, SQZ, GMDA, ELOX, ALBT, GMDAQ, AKAN, and SINT
Should you be buying Acorda Therapeutics stock or one of its competitors? The main competitors of Acorda Therapeutics include Scinai Immunotherapeutics (SCNI), Acorda Therapeutics (ACORQ), TC Biopharm (TCBP), SQZ Biotechnologies (SQZ), Gamida Cell (GMDA), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Gamida Cell (GMDAQ), Akanda (AKAN), and Sintx Technologies (SINT). These companies are all part of the "medical" sector.
Scinai Immunotherapeutics (NASDAQ:SCNI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
Acorda Therapeutics received 471 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users.
Scinai Immunotherapeutics has a net margin of 0.00% compared to Scinai Immunotherapeutics' net margin of -214.95%. Acorda Therapeutics' return on equity of 0.00% beat Scinai Immunotherapeutics' return on equity.
In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 1 articles in the media. Scinai Immunotherapeutics' average media sentiment score of 0.00 beat Acorda Therapeutics' score of -1.00 indicating that Acorda Therapeutics is being referred to more favorably in the news media.
58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 12.7% of Acorda Therapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 2.6% of Acorda Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Scinai Immunotherapeutics has higher earnings, but lower revenue than Acorda Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Scinai Immunotherapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.
Summary
Scinai Immunotherapeutics beats Acorda Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Acorda Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acorda Therapeutics Competitors List
Related Companies and Tools
